MarketMoodz
Amgen Shares Dip as Kissei Urges Caution on Tavneos Use
Kissei Pharmaceutical has begun alerting Japanese doctors to carefully evaluate use of Tavneos (avacopan), advising against new prescriptions and recommending reassessment of ongoing treatment amid safety and regulatory concerns in the U.S. and Europe. The guidance, reported in market press, comes as FDA and EMA scrutiny intensifies and has weighed on Amgen shares.
Key Takeaways
- Kissei told Japanese physicians to avoid starting new patients on Tavneos and to reassess current treatments because of liver-dysfunction risks and available alternatives.
- Tavneos has been marketed in Japan since June 2022 under Kissei’s license from CSL Vifor, which holds rights from a 2017 deal.
- The FDA issued a safety warning in March about serious, sometimes fatal, liver injuries linked to Tavneos and in April proposed withdrawing approval.
- The EMA opened a data-integrity review in January, and Japanese authorities (PMDA/MHLW) are being kept informed as Kissei collects information.
- Amgen shares traded near $323.69, down about 0.8% at the time of the report, reflecting investor unease over regulatory risk to Tavneos exposure.
People Involved
- No specific individuals mentioned
Entities Involved
- Amgen Inc. (AMGN)Global biopharma with commercial and royalty exposure to Tavneos
- Kissei Pharmaceutical Co., Ltd.Japanese licensee and marketer for Tavneos; conducting information-sharing with physicians
- CSL ViforOriginal licensor of Tavneos; granted Kissei exclusive Japan rights in 2017
- ChemoCentryxDeveloper of avacopan/Tavneos; subject of FDA application review
- U.S. Food and Drug Administration (FDA)Regulator that issued March safety warnings and proposed April withdrawal
- European Medicines Agency (EMA)Regulator that launched a January data-integrity review
- Pharmaceuticals and Medical Devices Agency (PMDA)Japan’s drug regulator being coordinated with by Kissei
- Ministry of Health, Labour and Welfare (MHLW)Japanese health ministry being coordinated with by Kissei
- The Wall Street JournalReported about 20 deaths in Japan after Tavneos use; causality not established
MarketMoodz Analysis
For investors, Kissei’s cautionary notices in Japan translate into a tangible near-term revenue risk for Amgen. Tavneos is a niche, rare-disease therapy where Japanese uptake since its June 2022 launch contributes royalties and milestone potential to partners; a pullback in prescriptions reduces those cash flows and raises uncertainty around peak sales assumptions. The market reaction—shares roughly 0.8% lower at the time of the report—signals investors are repricing regulatory and postmarketing-risk exposure even if Tavneos represents a modest portion of Amgen’s broader oncology-driven valuation.
The broader regulatory backdrop sharpens the stakes. The FDA’s March safety communication about serious liver injuries, the agency’s April move to propose withdrawing approval, and the EMA’s data-integrity review create a domino effect: partner markets often mirror U.S./EU regulatory sentiment, and Kissei’s outreach shows how quickly that spillover can hit prescribing behavior. What to watch next: official statements from Kissei, PMDA or MHLW confirming guidance; any FDA final action or appeals; EMA findings; and Japanese prescription trends and safety reports. Those items will determine whether this episode is a temporary dampener or a material impairment to Tavneos’ commercial outlook and to any downstream royalties for Amgen.
Source: Original Article